Topical Dapsone (Aczone): Uses, Efficacy, and How It Compares to Retinoids

What Is Topical Dapsone and How Does It Work?

Topical dapsone is a sulfone antibiotic with anti-inflammatory properties, formulated as a gel for direct application to acne-prone skin. Unlike oral dapsone (used in dermatitis herpetiformis and leprosy), the topical version delivers the drug locally with minimal systemic exposure, reducing the risk of dose-dependent blood dyscrasias 1.

The mechanism in acne centers on neutrophil suppression. Dapsone inhibits myeloperoxidase (MPO), an enzyme that generates hypochlorous acid and other reactive oxygen species within neutrophils recruited to inflamed follicles 2. By dampening this oxidative burst, dapsone reduces the redness and swelling of inflammatory papules and pustules without relying on the retinoid receptor pathway. This makes it mechanistically distinct from every topical retinoid on the market.

The FDA first approved dapsone 5% gel (Aczone) in 2005 for acne vulgaris in patients aged 12 and older 3. A reformulated 7.5% once-daily gel followed in 2016, using a modified vehicle that improved drug delivery and allowed a single daily application 4. Pharmacokinetic data from the 7.5% approval showed mean steady-state plasma concentrations of dapsone at approximately 2.3 ng/mL, well below the threshold associated with hemolytic effects from oral dosing 3.

Clinical Trial Evidence for Dapsone Gel

Two identical Phase III randomized controlled trials (N = 3,010 combined) established the efficacy of dapsone 5% gel for moderate acne. At 12 weeks, the dapsone group achieved a statistically significant improvement in Acne Global Assessment success rates (differences of 9.3% and 9.9% vs. vehicle, P<0.001 for both) 1. Inflammatory lesion counts dropped by a mean of 48.8% with dapsone 5% vs. 40.8% with vehicle.

The 7.5% formulation was evaluated in two additional key trials (N = 4,340 total). These showed a 48.9% mean reduction in inflammatory lesions and a 40.4% mean reduction in non-inflammatory lesions at week 12, both significantly superior to vehicle 4.

A pooled subgroup analysis found that female patients derived an even larger treatment effect from dapsone gel than males. The American Academy of Dermatology (AAD) guidelines note this sex-based differential as clinically relevant when selecting acne therapies 5.

Dapsone vs. Tretinoin (Retin-A)

Tretinoin 0.025%, 0.1% cream or gel remains one of the most widely prescribed topical acne treatments.

The tradeoff is tolerability. Tretinoin causes a well-documented retinization period of 2 to 6 weeks, marked by peeling, erythema, burning, and dryness. For patients with sensitive skin, rosacea-prone complexions, or darker skin tones at higher risk of post-inflammatory hyperpigmentation from retinoid irritation, dapsone offers a gentler entry point.

There is no direct head-to-head RCT comparing dapsone gel to tretinoin for acne. Clinicians typically position tretinoin as stronger for comedonal (non-inflammatory) acne and dapsone as particularly useful for inflammatory-predominant presentations or as part of combination regimens. The AAD guidelines classify both as "recommended" options for mild-to-moderate acne 5.

Dapsone vs. Adapalene (Differin)

Adapalene 0.1% gel became the first over-the-counter retinoid for acne in 2016, expanding access to retinoid therapy without a prescription 6. It selectively targets RAR-beta and RAR-gamma, producing less irritation than tretinoin while still promoting comedolysis. A key 12-week RCT (N = 653) demonstrated a 63% reduction in inflammatory lesions and 50% in non-inflammatory lesions with adapalene 0.1% gel 7.

Adapalene's tolerability advantage over tretinoin is established, but it still causes retinization in most users. Dapsone causes no photosensitivity at all, making it the safest topical for outdoor lifestyles.

The two agents complement each other well. The combination was well tolerated, with no increase in local skin reactions beyond what each agent causes individually.

Dapsone vs. Tazarotene (Tazorac)

Tazarotene is the most potent topical retinoid approved for acne and is the only one also FDA-approved for psoriasis. It selectively binds RAR-beta and RAR-gamma with high affinity.

Tazarotene's potency-irritation tradeoff is exactly where dapsone fills a gap. Tazarotene is poorly tolerated in eczema-prone or sensitive phenotypes. Dapsone gel requires no such workarounds.

A practical pairing used in clinical practice: tazarotene at night for its strong comedolytic effect and dapsone in the morning for anti-inflammatory coverage without stacking two irritants. No RCT validates this specific regimen, but the AAD guidelines support multi-mechanism combination therapy as a general acne principle 5.

Dapsone vs. Trifarotene (Aklief)

Trifarotene 0.005% cream, approved by the FDA in 2019, is the first topical retinoid designed for acne on the face and trunk simultaneously 8. It selectively agonizes RAR-gamma, the most abundant retinoic acid receptor in skin, achieving efficacy with lower systemic exposure than earlier retinoids. The PERFECT trials (two Phase III RCTs) showed trifarotene significantly improved facial and truncal acne, including inflammatory lesion counts, at 12 weeks vs. vehicle (P < .001) 9.

Trifarotene's local irritation profile falls between adapalene and tazarotene. In the PERFECT trials, trifarotene appeared safe and well tolerated 9. Dapsone gel again shows the mildest profile, but trifarotene covers truncal acne where dapsone has limited trial data.

For patients presenting with combined facial and truncal acne, trifarotene addresses both sites with a single product. For facial-only acne in irritation-sensitive individuals, dapsone is preferred. The two are not typically combined, given the limited evidence, though their mechanisms do not overlap.

Side Effects and Safety of Topical Dapsone

The most common adverse events with dapsone 7.5% gel in clinical trials were dryness (3.3%), peeling (2.2%), and erythema (1.6%), rates comparable to vehicle 4. Contact dermatitis occurs rarely and is typically allergic rather than irritant. The absence of a retinization phase represents one of dapsone's strongest clinical selling points.

The principal concern inherited from oral dapsone is hemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients. Reassuringly, pharmacokinetic studies of the topical formulation show that systemic dapsone levels remain far below the concentrations that trigger hemolysis with oral dosing (typically >2 mcg/mL). The FDA label does not require G6PD testing before topical use, though it recommends consideration in patients with known deficiency 3.

One important drug interaction: applying dapsone gel together with benzoyl peroxide can cause a temporary orange-brown discoloration of the skin. This is a cosmetic issue, not a safety concern, caused by oxidation of dapsone by benzoyl peroxide 10. Separating application times (BPO in the morning, dapsone at night, or vice versa) prevents this staining entirely. The 7.5% gel formulation appears less prone to this interaction due to its modified vehicle.

Who Should Consider Topical Dapsone?

Dapsone gel is best suited for specific patient profiles. Patients with inflammatory-predominant acne (papules and pustules more than comedones) respond most favorably based on the AAD's evidence review 5.

Patients who have failed or cannot tolerate topical retinoids gain a non-retinoid option with a distinct mechanism. Those with darker Fitzpatrick skin types (IV through VI) who are at high risk for retinoid-induced post-inflammatory hyperpigmentation may benefit from dapsone's low irritation potential 11.

Dapsone is also a rational add-on for patients already using a retinoid. For patients on systemic therapies like spironolactone or oral antibiotics who want a topical anti-inflammatory component, dapsone integrates easily without photosensitivity or antibiotic-resistance concerns.

One population where dapsone is less ideal: patients with purely comedonal acne (blackheads and whiteheads with no inflammatory component). Retinoids outperform dapsone for this presentation. Start with adapalene 0.1% gel for comedonal acne in a retinoid-naive patient, and reserve dapsone for inflammatory disease or retinoid-intolerant cases.